Talnetant

Talnetant

Systematic (IUPAC) name
3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
Identifiers
CAS Number	174636-32-9
ATC code	none
PubChem	CID 133090
IUPHAR/BPS	2124
ChemSpider	117450
UNII	CZ3T9T146K
Chemical data
Formula	C25H22N2O2
Molar mass	382.454 g/mol
SMILES CCC(C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)O
InChI InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29) Key:BIAVGWDGIJKWRM-UHFFFAOYSA-N
(what is this?)  (verify)

Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome however its use as a potential antipsychotic drug for the treatment of schizophrenia has been discontinued.^[1][2][3][4]

References

1. "UPDATE 1-GlaxoSmithKline prunes new drug pipeline". Reuters. Oct 15, 2007.
2. Evangelista S. Talnetant GlaxoSmithKline. Current Opinion on Investigational Drugs. 2005 Jul;6(7):717-21. PMID 16044668
3. Houghton LA, Cremonini F, Camilleri M, Busciglio I, Fell C, Cox V, Alpers DH, Dewit OE, Dukes GE, Gray E, Lea R, Zinsmeister AR, Whorwell PJ. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterology and Motility. 2007 Sep;19(9):732-43. PMID 17727393
4. Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J. In Vitro and In Vivo Characterization of the Non-peptide NK(3) Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia. Neuropsychopharmacology. 2008 Jun;33(7):1642-52. PMID 17728699